- •Patients with endometrioid ovarian cancer are more often diagnosed at early stage.
- •They are also younger, present more Lynch syndrome-associated cancers.
- •Endometrioid tumors are more frequently dMMR/MSI-high but have less BRCA1/2 mutations.
- •Endometrioid histology is independently associated with better PFS and OS.
Prognostic significance of endometrioid epithelial ovarian cancer (EOC) is controversial. We compared clinical, pathological, and biological features of patients with endometrioid and serous EOC, and assessed the independent effect of histology on outcomes.
We conducted a multicenter retrospective analysis of patients with EOC selected from the French Epidemiological Strategy and Medical Economics OC database between 2011 and 2016. Our main objective was to compare overall survival (OS) in endometrioid and serous tumors of all grades. Our second objectives were progression-free survival (PFS) and prognostic features.
Out of 10,263 patients included, 3180 cases with a confirmed diagnosis of serous (N = 2854) or endometrioid (N = 326) EOC were selected. Patients with endometrioid histology were younger, more often diagnosed at an early stage, with lower-grade tumors, more frequently dMMR/MSI-high, and presented more personal/familial histories of Lynch syndrome-associated cancers. BRCA1/2 mutations were more frequently identified in the serous population. Endometrioid patients were less likely to receive chemotherapy, with less bevacizumab. After median follow-up of 51.7 months (95CI[50.1–53.6]), five-year OS rate was 81% (95CI[74–85]) in the endometrioid subgroup vs. 55% (95CI[53–57] in the serous subset (p < 0.001, log-rank test). In multivariate analyses including [age, ECOG-PS, FIGO, grade, and histology], the endometrioid subtype was independently associated with better OS (HR = 0.38, 95CI[0.20–0.70], p = 0.002) and PFS (HR = 0.53, 95CI[0.37–0.75], p < 0.001).
Clinicopathological features at diagnosis are not the same for endometrioid and serous EOC. Endometrioid histology is an independent prognosis factor in EOC. These observations suggest the endometrioid population requires dedicated clinical trials and management.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
- Cancer statistics, 2018.CA Cancer J. Clin. 2018; 68: 7-30https://doi.org/10.3322/caac.21442
- WHO classification of tumours of female reproductive organs.International Agency for Research on Cancer, 2014
- Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study.Am. J. Obstet. Gynecol. 2020; 223 (107.e1-107.e11)https://doi.org/10.1016/j.ajog.2020.01.041
- ARID1A mutations in endometriosis-associated ovarian carcinomas.N. Engl. J. Med. 2010; 363: 1532-1543https://doi.org/10.1056/NEJMoa1008433
- Molecular profiling and molecular classification of endometrioid ovarian carcinomas.Gynecol. Oncol. 2019; 154: 516-523https://doi.org/10.1016/j.ygyno.2019.07.012
- An integrated molecular profile of endometrioid ovarian cancer.Gynecol. Oncol. 2020; 157: 55-61https://doi.org/10.1016/j.ygyno.2020.02.011
- Endometrioid carcinoma of the ovary: outcomes compared to serous carcinoma after 10 years of follow-up.J. Obstet. Gynaecol. Can. 2017; 39: 34-41https://doi.org/10.1016/j.jogc.2016.10.006
- Invasive epithelial ovarian cancer survival by histotype and disease stage.JNCI J. Natl. Cancer Inst. 2019; 111: 60-68https://doi.org/10.1093/jnci/djy071
- Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000-2013.Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017; 28: 2985-2993https://doi.org/10.1093/annonc/mdx525
- The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the epidemiological strategy and medical economics (ESME).BMJ Open. 2019; 9e023568https://doi.org/10.1136/bmjopen-2018-023568
- EP967 natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment.Int. J. Gynecol. Cancer. 2019; 29https://doi.org/10.1136/ijgc-2019-ESGO.1013
- Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2016; 27: 1725-1732https://doi.org/10.1093/annonc/mdw260
- Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.Eur. J. Cancer Oxf. Engl. 1990. 2018; 95: 93-101https://doi.org/10.1016/j.ejca.2018.03.013
- Impact of body mass index on overall survival in patients with metastatic breast cancer.Breast Edinb. Scotl. 2020; 55: 16-24https://doi.org/10.1016/j.breast.2020.11.014
- Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration.PLoS Med. 2007; 4e297https://doi.org/10.1371/journal.pmed.0040297
- Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.Gynecol. Oncol. 2008; 109: 370-376https://doi.org/10.1016/j.ygyno.2008.02.006
- Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades.Am. J. Obstet. Gynecol. 2003; 189: 1120-1127
- FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.Semin. Surg. Oncol. 1994; 10: 31-46https://doi.org/10.1002/ssu.2980100107
- Long-term results and prognostic factors in patients with epithelial ovarian cancer.Gynecol. Oncol. 2000; 78: 21-27https://doi.org/10.1006/gyno.2000.5805
- Survival among U.S. women with invasive epithelial ovarian cancer.Gynecol. Oncol. 2002; 84: 399-403https://doi.org/10.1006/gyno.2001.6536
- The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.Gynecol. Oncol. 1995; 56: 175-180https://doi.org/10.1006/gyno.1995.1027
- Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007; 25: 3621-3627https://doi.org/10.1200/JCO.2006.10.2517
- Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2010; 20: 945-952https://doi.org/10.1111/IGC.0b013e3181dd0110
- Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.Gynecol. Oncol. 2001; 81: 398-403https://doi.org/10.1006/gyno.2001.6172
- The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?.Br. J. Cancer. 2008; 98: 1191-1196https://doi.org/10.1038/sj.bjc.6604299
- Natural history and outcome of mucinous carcinoma of the ovary.Am. J. Obstet. Gynecol. 2011; 205 (480.e1-480.e8)https://doi.org/10.1016/j.ajog.2011.06.049
- Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG oncology/gynecologic oncology group ancillary data study.Gynecol. Oncol. 2018; 148: 275-280https://doi.org/10.1016/j.ygyno.2017.11.018
- Who are the long-term survivors of high grade serous ovarian cancer?.Gynecol. Oncol. 2018; 148: 204-212https://doi.org/10.1016/j.ygyno.2017.10.032
- Characteristics of long-term survivors of epithelial ovarian cancer.Obstet. Gynecol. 2015; 126: 491-497https://doi.org/10.1097/AOG.0000000000000981
- Prognostic significance of endometrioid ovarian cancer subtype: results of an international multi-institutional retrospective study.Int. J. Gynecol. Cancer. 2017; 27: 1562
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019; https://doi.org/10.1093/annonc/mdz062
- Gynecologic cancers associated with Lynch syndrome/HNPCC.Clin. Transl. Oncol. Off. Publ. Fed. Span Oncol. Soc. Natl. Cancer Inst. Mex. 2008; 10: 313-317https://doi.org/10.1007/s12094-008-0206-9
- Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Mol. Oncol. 2009; 3: 97-137https://doi.org/10.1016/j.molonc.2009.02.004
- Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary.Gynecol. Oncol. 2014; 135: 81-84https://doi.org/10.1016/j.ygyno.2014.07.100
- Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.Clin. Cancer Res. 2008; 14: 6847-6854https://doi.org/10.1158/1078-0432.CCR-08-1387
- Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.Int. J. Cancer. 2011; 129: 1914-1922https://doi.org/10.1002/ijc.25835
- Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.Cancer Med. 2021; https://doi.org/10.1002/cam4.3688
- PD-1 blockade in tumors with mismatch-repair deficiency.N. Engl. J. Med. 2015; 372: 2509-2520https://doi.org/10.1056/NEJMoa1500596
- Hereditary cancer syndromes-a primer on diagnosis and management: part 1: breast-ovarian cancer syndromes.Mayo Clin. Proc. 2019; 94: 1084-1098https://doi.org/10.1016/j.mayocp.2019.02.017
- Clinical activity and safety of the anti–programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial.JAMA Oncol. 2020; https://doi.org/10.1001/jamaoncol.2020.4515
- Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.Gut. 2017; 66: 464-472https://doi.org/10.1136/gutjnl-2015-309675
- Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.N. Engl. J. Med. 2019; 381: 2416-2428https://doi.org/10.1056/NEJMoa1911361
- Niraparib in patients with newly diagnosed advanced ovarian cancer.N. Engl. J. Med. 2019; 381: 2391-2402https://doi.org/10.1056/NEJMoa1910962
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2017; 18: 1274-1284https://doi.org/10.1016/S1470-2045(17)30469-2
- Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.N. Engl. J. Med. 2016; https://doi.org/10.1056/NEJMoa1611310
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Lond. Engl. 2017; 390: 1949-1961https://doi.org/10.1016/S0140-6736(17)32440-6
- Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer.N. Engl. J. Med. 2018; 379: 2495-2505https://doi.org/10.1056/NEJMoa1810858
- Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.Lancet Oncol. 2012; 13: 385-394https://doi.org/10.1016/S1470-2045(11)70404-1
Published online: July 19, 2021
Accepted: July 11, 2021
Received in revised form: July 8, 2021
Received: May 4, 2021
© 2021 Elsevier Inc. All rights reserved.